No additional benefit of HRT on response to rivastigmine in menopausal women with AD.
Rigaud
A S
AS
Department of Geriatrics, Broca Hospital, Paris, France. anne-sophie.rigaud@brc.ap-hop-paris.fr
André
G
G
Vellas
B
B
Touchon
J
J
Pere
J J
JJ
D000203:Activities of Daily Living; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D002219:Carbamates / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage; D005260:Female; D005602:France; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008593:Menopause / Q000187:drug effects; D009483:Neuropsychological Tests; D048448:Phenylcarbamates; D011374:Progesterone / Q000008:administration & dosage; D000068836:Rivastigmine; D016896:Treatment Outcome
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D011374:Progesterone; D004958:Estradiol; D000068836:Rivastigmine